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interactions among HBV, hepatocytes, and the host 
immune system. Natural history studies of chronic 
hepatitis B (CHB) infection have shown an association 
between active viral replication and adverse clinical 
outcomes such as cirrhosis and hepatocellular carcinoma. 
The goal of therapy for CHB is to improve quality of life 
and survival by preventing progression of the disease 
to cirrhosis, decompensation, end-stage liver disease, 
hepatocellular carcinoma (HCC) and death. This goal 
can be achieved if HBV replication is suppressed in 
a sustained manner. The accompanying reduction in 
histological activity of CHB lessens the risk of cirrhosis 
and of HCC, particularly in non-cirrhotic patients. 
However, CHB infection cannot be completely eradicated, 
due to the persistence of covalently closed circular DNA 
in the nucleus of infected hepatocytes, which may explain 
HBV reactivation. Moreover, the integration of the HBV 
genome into the host genome may favour oncogenesis, 
development of HCC and may also contribute to HBV 
reactivation.
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Core tip: The goal of therapy for chronic hepatitis B 
is to improve quality of life and survival by preventing 
progression of the disease to cirrhosis, decompensation, 
end-stage liver disease, hepatocellular carcinoma and 
death. Current therapeutic options do not eradicate 
hepatitis B virus (HBV) infection, since HBV remains 
either integrated in the host genome or in the nuclei of 
hepatocytes as covalently closed circular DNA, a fact that 
may favour oncogenesis towards the development of 
hepatocellular carcinoma, and explains HBV reactivation. 
It is mandatory for clinicians to start viral suppression in 
patients with active chronic liver disease, particularly in 
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Role of antiviral therapy in the natural history of hepatitis B 
virus-related chronic liver disease
patients who have already developed advanced hepatic 
disease.
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INTRODUCTION
Hepatitis B virus (HBV) infection is one of the most 
serious health problems worldwide. It has been 
estimated that almost one third of world’s population has 
serological evidence of past or actual exposure to HBV[1,2] 
and 350-400 million people are chronically infected[1,3,4]. 
More than 780000 people die every year due to the 
consequences of hepatitis B[5].
The natural history of HBV infection and of the ensuing 
liver disease is variable and complex. HBV infection is a 
dynamic state of interactions among HBV, hepatocytes, 
and the host’s immune system. The resultant hepatic 
necro-inflammatory response to injury, reflected by 
alanine aminotransferase elevation or hepatitis activity, 
may stimulate, during the immune clearance phase, new 
fibrogenesis that may even lead to progressive fibrosis, 
causing architectural distortion and cirrhosis. This process 
may culminate in end-stage liver disease with portal 
hypertension and may also lead to the development 
of hepatocellular carcinoma (HCC)[6]. Approximately 
15% to 40% of infected patients who develop chronic 
hepatitis B are expected to progress to cirrhosis and 
eventually to end-stage liver failure[4,7]. These data have 
been confirmed in Italy as well, where the HBe-negative/
anti-HBe-positive type of chronic B hepatitis (CHB) is 
predominant, and the 5-year incidence of cirrhosis has 
been estimated to be 38%[4].
Although it has been generally held true that ad-
vanced fibrosis, once present, is static and irreversible, 
evidence is accumulating to suggest that fibrogenesis is 
a dynamic process, amenable to arrest or possibly even 
reversal with removal of the inciting agent[8]. Analogous 
to the improvement observed with continued abstinence 
in alcoholic liver disease, with immunosuppression 
in chronic autoimmune hepatitis, with weight loss 
in steatohepatitis, and with clearance of hepatitis C 
virus with interferon and ribavirin, suppression of HBV 
replication and loss of hepatitis B e antigen (HBeAg) or 
hepatitis B surface antigen (HBsAg) with antiviral therapy 
may prevent progressive fibrosis and decompensation.
Recently, concerns have been raised regarding 
the long-term benefit of HBeAg seroconversion for 
such patients. Although some observational studies 
suggest that most Asian patients experience some 
clinical benefit after HBeAg seroconversion[9,10], this is 
still an incomplete marker of immune control. HBeAg 
seroconversion associated with incomplete viral 
suppression may result in the emergence of precore 
mutant hepatitis B, with its expected chronic sequelae.
It has been demonstrated that active replication 
of HBV constitutes the principal trigger for immune 
clearance, which, in turn, has an impact on clinical 
outcome[11,12]. Therefore, treatment is primarily aimed at 
eliminating or permanently suppressing HBV, reducing 
the activity of hepatitis and slowing down or limiting 
the progression of hepatic injury. Ultimately, the goals 
of therapy are prevention or reduction of the risk of 
developing hepatic decompensation, cirrhosis or HCC, 
and prolonging survival, through the achievement of 
sustained viral response and clearance of HBsAg[6].
Several pharmacologic agents including standard 
interferon (IFN), lamivudine (LAM), pegylated IFN 
(PEG-IFN), adefovir dipivoxil (ADV), telbivudine (LdT), 
entecavir (ETV), and tenofovir disoproxil fumarate 
(TDF) are capable of fulfilling the goals of therapy and 
have been established as treatment of chronic HBV 
infection[1].
Moreover, both short- and long-term outcomes 
of patients with chronic HBV infection are improved, 
and this will be the focus of this review. Indeed, in this 
review we will address the following issues: (1) How 
antiviral therapy may influence fibrosis progression 
and resolution; (2) The role of the antiviral therapy in 
patients with decompensated liver disease; and (3) The 
role of the antiviral therapy in reducing the risk of HCC.
ANTIVIRAL THERAPY, FIBROSIS 
PROGRESSION AND RESOLUTION
Injury, may it be chronic or acute, elicits a cellular- and 
cytokine-mediated healing response aimed at limiting or 
encapsulating injury, which results in fibrosis or scarring 
of the liver. Damage caused by infections, drugs, 
metabolic disorders or immunological alterations, and 
which is maintained in time, promotes the accumulation 
of significant fibrosis[12].
Hepatic fibrosis is mainly stimulated by hepatic 
necro-inflammatory activity, and several studies have 
shown that prolonged antiviral therapy is associated 
with improvement in liver histology and even reversal 
of cirrhosis in CHB infection.
Patients who respond to interferon therapy have 
substantially fewer life-threatening liver complications 
than non-responders[13], although the evidence of the 
effect of this therapy on the incidence of hepatocellular 
carcinoma is less conclusive[14-16]. However, the use of 
interferon is restricted by costs, side effects, and among 
patients with advanced liver disease or cirrhosis, due to 
the risk of liver failure correlated with hepatitis flares. 
These limitations do not apply to oral nucleos(t)ide 
anologues-(NUCs), such as Lam and/or ADV, agents that 
have been used for decades, and the more recent agents 
ETV, Ldt or TDF. These drugs can produce marked viral 
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suppression, reduction of hepatic necro-inflammatory 
activity, histologic improvement of liver fibrosis, and 
amelioration of liver function, even in patients with 
decompensation. One of the first pieces of evidence in 
favor of this statement was established when a reduced 
risk of liver complications was demonstrated in patients 
affected by CHB with advanced fibrosis or cirrhosis who 
were treated with LAM. The magnitude of protection 
conferred by LAM was substantial, with a reduction of 
approximately 50% in disease progression during a 
median period of 32 mo of treatment[17]. Dienstag et al[18] 
confirmed these data showing histological improvement 
and a reduction in fibrosis score to non-cirrhotic levels in 
more than 70% of patients treated with LAM with pre-
treatment cirrhosis; the proportion was similar regardless 
of the presence of a tyrosine-methionine-aspartate-
aspartate variant. Also noteworthy was the fact that 
only 2% of non-cirrhotic patients progressed to cirrhosis 
over this 3.5-year. Sampling error, however, could have 
perhaps contributed to the observed regression of 
cirrhosis in these patients, although this is unlikely the 
case for all patients. 
Significant improvement in liver histology was also 
observed following long-term treatment with ADV. The 
median change in Knodell necro-inflammation score 
from the time patients were started on ADV was of 4.5 
points at 192 wk and of 5.0 points at 240 wk, and the 
median change in Ishak fibrosis score was of 1.0 point 
for both groups. After 48 wk of treatment with adefovir 
dipivoxil, treatment with adefovir dipivoxil resulted 
in an increase in the proportion of patients who had 
improvement of at least 1 point according to Ishak 
from 35% after 48 wk to 55% and 71% after 192 and 
240 wk of treatment, respectively. Of twelve patients 
with pre-treatment bridging fibrosis or cirrhosis, seven 
(58%) demonstrated an improvement of at least 2 
points in their Ishak fibrosis scores, while a 4-point 
histologic improvemement was observed in 3 of 4 
patients with cirrhosiss[19]. In another study comparing 
post- and pre-treatment biopsies in patients treated 
with ADV, significant improvement of hepatic necro-
inflammation and fibrosis was observed[20].
Although LAM and ADV have been associated 
with reversal of fibrosis and cirrhosis, their long-term 
efficacy has been limited by the emergence of antiviral 
resistance[18,19]. After treatment with lamivudine for 3 
years, 72% of patients with cirrhosis show histologic 
improvement and a reduction in fibrosis score to non-
cirrhotic levels. However, in the same study, 65% of 
the cohort (41 of 63 patients) developed resistance, 
including one patient with cirrhosis, who also experienced 
progression of liver disease at follow-up. Virologic 
resistance emerged in 20% of the patients treated for 5 
years with ADV[18].
For this reason, high genetic barrier treatment 
regimens have been adopted during the last years, 
such as ETV, LdT and tumor necrosis factor. Nucleoside-
naive, HBeAg(+) and HBeAg(-) patients with cirrhosis/
advanced fibrosis at baseline (Ishak fibrosis score, ≥ 
4) and at least 3 years of ETV treatment demonstrate 
durable suppression of HBV replication, improvement in 
liver histology, and reversal of fibrosis/cirrhosis[21]. After 
a median exposure of approximately 6 years to ETV 
therapy, histological improvement was observed, with 
a reduction or stability of necroinflammatory score in 
96% and reduction of fibrosis in 88% of patients. Most 
patients (75%) in the cohort who had a F4 baseline 
HAI score achieved a F3 score by the time of long-term 
biopsy. No evidence of virological rebound or genotypic 
resistance to entecavir was observed in this study[22].
In a multicentre study, Marcellin et al[23] analyzed 
the long-term efficacy and safety of of TDF as well 
as sequential histological data obtained for 5 years in 
348 patients, 96 of whom had been diagnosed with 
cirrhosis at baseline. HBV DNA was undetectable 
in almost all patients treated with TDF, associated 
with prevention of fibrosis progression in 96% of the 
patients overall, and with cirrhosis regression in 74% 
of patients. Furthermore, a high genetic barrier was 
demonstrated for TDF, with no evidence for emergence 
of resistant variants during 5 years of treatment. 
Although this study provides solid evidence for fibrosis 
regression, some experts believe that once established, 
parenchymal destruction and disrupted blood flow in 
cirrhosis are irreversible. A study showed that hepatic 
venous pressure gradient (HVPG) was reduced in 18 
of 19 cirrhosis patients treated with LAM for 12 mo, 
whereas portal pressure was reduced at least 20% or 
below 12 mmHg in 10 of 13 patients in whom baseline 
HVPG was ≥ 12 mmHg, suggesting that vascular 
changes in cirrhosis are reversible in patients with 
virological and biochemical response[24]. Thus, it seems 
fairly clear that aside from abatement of HCC incidence 
demonstrated in the study by Marcellin et al[23] cirrhosis 
is to some degree reversible in patients with sustained 
HBV suppression and annulled hepatitis activity with 
NUC treatment. 
ANTIVIRAL THERAPY AND 
DECOMPENSATED LIVER DISEASE
Ascites, hepatic encephalopathy, jaundice, and variceal 
bleeding represent decompensation milestones in the 
natural history of an individual cirrhotic patient[25]. 
In HBV-related cirrhosis, the reported yearly rate of 
decompensation is 2%-5%[26], and this event can 
present as part of an acute hepatitis flare or in a more 
insidious manner[27,28]. 
Decompensation entails an ominous prognosis, as 
the 5-year survival rate drops from 84% in compensated 
cirrhosis to 14%-35% once decompensation has 
ensued[29,30]. A bulk of evidence indicates that the risk 
of disease progression is closely linked to a patient’s 
serum HBV DNA level[30-34]. Indeed, a study analyzing 
161 patients followed for a median of 6.6 years showed 
that the risk of hepatic decompensation was 4 times 
higher in HBV DNA positive patients (13%-18%) vs in 
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analysis of two studies, SAE affected 6% of patients 
treated with ETV[43]. Similar frequency of SAE with 
ADV and ETV were reported in one prospective study, 
whereas EDF and ETV were associated with similar 
SAE rates (4% vs 0%, P = 0.89) and (7% vs 9%, P 
= 0.72), respectively[43,44]. Under ADV treatment, 9% 
(5%-17%) of patients developed renal insufficiency 
(defined as an increase in serum creatinine by 0.5 
mg/dL over the baseline) occurred in, while this 
complication was present in 10% (6%-17%) of patients 
treated with ETV. No cases of renal insufficiency are, 
on the contrary, reported with LAM. Moreover, renal 
function improvement (expressed as an increase in 
estimated glomerular filtration rate from baseline) was 
significantly greater in patients treated with LdT with 
respect to patients on LAM therapy (3.3 ± 3.3 mL vs 
4.3 ± 3.1 mL, P = 0.02), according to a prospective 
randomised controlled trial on LdT and LAM[45]. The 
frequency of renal insufficiency at 1-year after starting 
antiviral treatment was reportedly similar between ETV- 
and TDF-treated patients (5% vs 9%, P = 0.53) in a 
different study[44]. 
ANTIVIRAL THERAPY AND THE RISK OF 
HCC
The third cause of malignancy-related death in the 
world, HCC commonly arises in patients with pre-
existing cirrhosis or chronic liver disease[46]. Seventy-
eight percent of HCCs are related to CHB and chronic 
hepatitis C infections, occurring approximately in the 
ratio of 7 to 3, respectively[47]. Different etiologies of 
liver disease are associated with a greater or lesser 
risk of HCC, and CHB is the principal underlying cause 
worldwide[48].
The intricate mechanisms by which the action of 
the established carcinogen HBV triggers the onset of 
HCC have not yet been well established. Presumably, 
the integration of HBV’s DNA into the host genome, 
alongside the direct effect of viral proteins on the 
hepatocyte are both key components of the direct 
carcinogenic effect of HBV on hepatocytes. However, 
possibly the paramount driver of HCC development 
is the inflammation elicited by HBV, leading to the 
establishment of cirrhosis, which is almost invariably 
present in patients with HCC[49]. 
Not strangely, marked geographical differences in 
HCC incidence coincide with the prevalence of CHB. 
While in Scandinavia, the United States, and Canada, 
incidence is approximately less than 5 cases per 
100000, incidence rates peak in central and southeast 
Asia, with incidence rates that vary from 29 to 99 
per 100000[50]. Apart from the solid epidemiological 
association between the incidence of HCC and the 
prevalence of CHB, numerous other observations 
point towards an etiologic link between CHB and the 
development of HCC[51]. The prevalence of HBsAg is 
high amongst patients with HCC and HBsAg carriers 
HBeAg negative/HBV DNA negative patients (4%, P 
= 0.04)[34]. Persistent HBeAg seropositivity was shown 
to be significantly (P = 0.035) associated with the 
probability of decompensation in a study analyzing 93 
patients with newly developed cirrhosis, and patients in 
whom HBeAg was persistently positive had a 6 times 
higher risk of decompensation compared to HBeAg 
seronegative subjects at entry, during a mean follow-up 
period of 102 mo[35].
Although it is recommended to commence antiviral 
treatment as soon as CHB is diagnosed, IFN use, even at 
low doses, increases the risk of bacterial infections and 
may provoke an episode of hepatic decompensation. 
In the era of NUCs, interferon is contraindicated in this 
patient population[1]. Patients with decompensated 
cirrhosis may show slow clinical improvement over 
a period of 3-6 mo under NUCs, after which trans-
plantation may be avoided. In such cases, life-long 
treatment is recommended[1]. In contrast, some patients 
with advanced hepatic disease reflected by a high Child-
Turcotte-Pugh (CTP) or model of end stage liver disease 
(MELD) score, may have progressed beyond the 
point of no return, and may not benefit from medical 
therapy, thus requiring liver transplantation[36]. In that 
situation, treatment with NUCs which induces HBV 
DNA undetectability at transplantation will decrease 
the risk of HBV recurrence in the graft[37].
LAM has been demonstrated to enact an effective 
suppression of HBV DNA replication and to significantly 
ameliorate liver function in decompensated CHB[38,39]. 
A major drawback of LAM, however, lies in its frequent 
association with resistant mutants and therefore 
elevated drug resistance rates[40]. However, the choice 
of the most adequate antiviral agent at a later disease 
stage often becomes remarkably difficult, due to 
the relentless and rapid progression of disease and 
poor liver function. In the last years, researchers 
have tried to identify the risk factors for developing 
decompensation or early signs of non-response to 
therapy. Post-treatment response was comparatively 
poor for cases with a cut-off of CTP > 10, MELD > 20, 
HBV DNA > 7.4 log and total bilirubin > 3.7 mg/dL (P < 
0.05). Srivastava et al[41] showed that a MELD score > 
20 was the most potent predictor of mortality among all 
the factors considered, and that these patients should 
be considered for orthotopic liver transplantation. In 
the same paper, the clinical efficacy of antiviral therapy 
with TDF was proven and showed a rescue activity, 
achieving more than 90% survival at one year and 
> 80% survival at 2 years in decompensated Child C 
cirrhosis[41].
A further issue to discuss regarding antiviral therapy 
in decompensated cirrhosis due to HBV is the possible 
occurrence of adverse events. Whereas the safety of 
LAM has been established, with no reported serious 
adverse events (SAE), ADV has been reportedly 
associated with SAE in 4% of patients, including 
2% of treated patients with hypophosphatemia in a 
study analyzing 226 treated patients[42]. In a pooled 
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have a 98-fold increased relative risk for developing 
HCC with respect to HBsAg-negative subjects. Further 
strengthening the evidence in favor of this correlation 
are the fact that integrated HBV-DNA has been found 
within neoplastic HCC cells, the recognition that HBV 
vaccination has been followed by a decrease in HCC 
incidence, and the observation of an elevated risk of 
HCC development in animal models of CHB[52]. 
Preventing disease progression and HCC develop-
ment in HBV-infected patients is mandatory[53]. As 
already mentioned, the current therapeutic options 
for patients with CHB infection may be summarized 
into treatment with standard or PEG-IFN, a drug with 
antiviral, immunomodulatory and perhaps antitumoral 
activities, as well as treatment with oral NUC[1]. 
In terms of prevention of HCC, IFN therapy, which 
stimulates immunological check of viral replication, 
might theoretically represent an advantage regarding 
prevention of HCC. On the contrary, NUC therapy is 
likely to represent an advantage over IFN if the direct 
carcinogenic effect of HBV DNA levels occupies a 
more preponderant role. Numerous studies and meta-
analyses have analyzed the impact of IFN on HCC 
incidence in patients with CHB, concluding that probably 
a reduction in the overall incidence of HCC can be 
obtained with the use of IFN, and that this reduction is 
more important in patients who maintain a sustained 
viral reponse. These effect has been more clearly 
demonstrated in Asian studies vs European studies, 
probably due to the fact that HCC incidence is higher in 
Asia[15,54-56]. The effect of oral antiviral therapy on HCC 
incidence, however, has not been clarified.
It has been shown that long-term NUC therapy 
with initial lamivudine monotherapy is not effective in 
abolishing the risk of developing HCC risk in HBeAg-
negative patients with CHB, particularly in subjects 
with cirrhosis at baseline. Established independent risk 
factors for HCC development in CHB patients even after 
NUC treatment include older age and male gender[57]. 
Although induction and maintenance of virological 
suppression appears not to significantly diminish overall 
incidence of HCC, virological remission on-therapy 
might be protective in HBeAg-negative patients with 
CHB but no cirrhosis. On the contrary, as patients with 
established cirrhosis still stand a high risk of HCC even 
with an effective antiviral therapy, strict surveillance is 
warranted[57]. 
The reduction of the risk of developing HCC is 
largely dependent upon an agent’s capacity to maintain 
virological remission. In fact, patients in whom a virologic 
breakthrough is observed, the risk of developing HCC 
is increased, notwithstanding subsequent suppression 
of viral replication with rescue therapy. This observation 
constitutes another element against the use of lamivudine 
as the first-line treatment of choice, due to its association 
with high resitance rates during long-term treatment[58]. 
In a recent randomized controlled trial, Huang et 
al[59] showed that in patients with hepatitis B-related 
HCC treated with adefovir, antiviral therapy leads to 
a reduction of late HCC recurrence and significantly 
improves overall survival after hepatic resection, as 
opposed to no treatment at all. 
In a recent update of the HEPNET Greece cohort 
study, the authors compared ETV with LAM, showing a 
lower HCC incidence (of 0.3%, 1.2%, 2.8% vs 0.7%, 
3.8%, 5.6% at 1, 3, and 5 years, respectively; P = 
0.024) in the first group. However, in the multivariable 
Cox regression analysis, the HCC risk was independently 
associated with older age (P < 0.001), male gender (P 
= 0.011) and cirrhosis (P = 0.025), but not with the 
initial antiviral agent[60]. 
Finally, two recent papers showed that antiviral 
treatment with ETV did not completely eliminate the 
risk of developing HCC in patients with cirrhosis[61,62]. 
These data were confirmed in a recent, large, real-life 
multicenter United States-based observational cohort 
study, in which antiviral therapy was associated with a 
significant decrease in the risk of HCC in patients with 
chronic HBV infection, but did not eliminate it[47]. 
In conclusion, it is clear that only with treatments 
that can completely eradicate the virus from the 
liver will we be truly able to eliminate the risk of HCC 
development in patients with HBV-related liver disease.
CONCLUSION
Treatment for CHB infection aims to maximize viral 
suppression with the objective of controlling liver fibrosis 
and preventing progression to clinical complications 
associated with hepatic decompensation and hepato-
cellular carcinoma. Since necroinflammatory activity 
is the main stimulator of hepatic fibrosis[12] amidst the 
intricate pathways leading to HCC development in chronic 
viral hepatitis[63], it is conceivable that the fibrogenic 
process will be arrested or even down-graded along 
with the subsidence of hepatitis activity subsequent to 
HBV suppression[64]. On the other hand, maintaining 
undetectable levels of HBV DNA may also increase the 
rate of HBeAg and HBsAg seroconversion, which are the 
desired endpoints of CHB therapy[65]. 
Notwithstanding the solid evidence of viral replication 
blockade with approved antivirals, the demonstration 
of advantages in terms of long-term outcomes is 
more difficult. This is due to the fact that clinical 
complications develop over decades, and clinical trials 
with necessarily lengthy follow-up periods are difficult, 
if not impossible, to perform. In decompensated HBV 
patients, the waxing frequency of resistance to LAM, 
ADV and LdT monotherapy, render these three drugs 
less appropriate. Antiviral therapy using newer NUCs 
with lower resistance rates such as ETV or TDF could 
suppress HBV replication, improve liver function in 
patients with compensated or decompensated cirrhosis, 
delay or obviate the need for liver transplantation in 
some patients, and reduce the risk of HBV reactivation.
Finally, current therapeutic options do not eradicate 
HBV infection and in spite of adequate treatment, the 
virus remains indefinitely in a latent state, representing 
Russo FP et al . Therapy for chronic hepatitis B
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a continuous threat of reactivation and of oncogenic 
potential leading to HCC development. It is nevertheless 
mandatory for clinicians to start viral suppression in 
patients with active chronic liver disease, in particular 
with those that have already developed advanced hepatic 
disease, with the aim of avoiding future complications 
and hopefully reversing at least some degree of hepatic 
damage. 
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